Anticoagulant, Anti-platelet and Thrombolytic Drugs Flashcards
Haemostasis
Arrest of blood loss blood from damaged vessel
Haemostasis pathogenesis
- Vascular wall damage, exposes collagen and tissue factors
- Local vasoconstriction
- Platelet adhesion, activation and aggregation
- Activation of blood clotting and formation of a stable clot
TXA2
Synthesised and released by activated platelets
Binds to receptors releasing serotonin and ADP
ADP binds to platelet GPCR activating further platelets
Thrombosis
Pathological haemostasis
Arterial thrombus
White
Mainly platelets in a fibrin mesh
Forms embolus if detaches that often lodges in brain
Treated with anti-platelet drugs
Venous thrombus
Red
Jelly-red tail and fibrin rich
Forms embolus if detached that will often lodge in lung
Treated with anticoagulants
Warfarin
Anticoagulant Competitive inhibitor of vitamin K Blocks in vivo not in vitro Slow onset of action, long half life Low therapeutic index Risk of haemorrhage
Risk factors for haemorrhage on warfarin
make warfarin work too well
Liver disease
High metabolic rate
Drugs inhibiting platelet function (aspirin)
Drugs that decrease availability of vitamin K
Factors that increase risk of thrombosis on warfarin
don’t allow warfarin to work well enough
Physiological state (pregnancy)
Vitamin K consumption
Drugs that increase metabolism of warfarin
Heparin
Anti-coagulant
Binds to antithrombin III, increasing affinity for serine protease clotting factors , increasing rate of their activation
Adverse effects of heparin
Haemorrhage
Osteoporosis (longer term)
Hypersensitivity reactions
Anti-platelet drugs
used for arterial thrombosis
Anti-coagulant drugs
used for venous thrombosis
Aspirin
Irreversibly blocks COX, preventing TXA2 synthesis and inhibits production of antithrombotic prostoglandin
Adverse effects of aspirin
GI bleeding and ulceration